Dr. Levy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1065Fax+1 214-370-1190- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
- UPMC Medical EducationResidency, Internal Medicine, 1999 - 2002
- University of Wisconsin School of Medicine & Public HealthClass of 1999
Certifications & Licensure
- TX State Medical License 2008 - 2025
- MD State Medical License 2002 - 2010
- PA State Medical License 2000 - 2002
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Xu, L., Shadman, M., Flinn, I., Levy, M., Porter, R., Burke, J., Zafar, S., Cultrera, J., Misleh, J., Kingsley, E., Yimer, H., Freeman, B., Chaudhry, A., Tumula, P., G...> ;Haematologica. 2024 Jan 25
- 8 citationsElranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, A...> ;Nature Medicine. 2023 Oct 1
- 3 citationsTreatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.Neil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa G...> ;British Journal of Haematology. 2023 Sep 1
- Join now to see all
Lectures
- Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial ResultsAugust 13th, 2020
Hospital Affiliations
- Baylor University Medical CenterDallas, Texas
- Medical City DallasDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: